Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
M Filippi, MP Amato, D Centonze, P Gallo… - Journal of …, 2022 - Springer
Multiple sclerosis (MS) is a chronic and progressive neurological disease that is
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …
Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis
Early intervention with high-efficacy disease-modifying therapy (HE DMT) may be the best
strategy to delay irreversible neurological damage and progression of multiple sclerosis …
strategy to delay irreversible neurological damage and progression of multiple sclerosis …
Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management
C Oreja-Guevara, S Martínez-Yélamos… - Therapeutic …, 2024 - journals.sagepub.com
Recent advances in multiple sclerosis (MS) management have shifted perspectives on
treatment strategies, advocating for the early initiation of high-efficacy disease-modifying …
treatment strategies, advocating for the early initiation of high-efficacy disease-modifying …
To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection
D Stastna, I Menkyova, J Drahota, T Hrnciarova… - Multiple Sclerosis and …, 2022 - Elsevier
Background COVID-19 vaccination and infection are speculated to increase the activity of
immune-mediated diseases, including multiple sclerosis (MS) and neuromyelitis optica …
immune-mediated diseases, including multiple sclerosis (MS) and neuromyelitis optica …
Brain volume loss in multiple sclerosis is independent of disease activity and might be prevented by early disease-modifying therapy
D Slezáková, P Kadlic, M Jezberová… - Neurologia i …, 2023 - journals.viamedica.pl
Introduction. Neurodegeneration is likely to be present from the earliest stages of multiple
sclerosis (MS). MS responds poorly to disease-modifying treatments (DMTs) and leads to …
sclerosis (MS). MS responds poorly to disease-modifying treatments (DMTs) and leads to …
Feasibility of detecting atrophy relevant for disability and cognition in multiple sclerosis using 3D-FLAIR
Background and objectives Disability and cognitive impairment are known to be related to
brain atrophy in multiple sclerosis (MS), but 3D-T1 imaging required for brain volumetrics is …
brain atrophy in multiple sclerosis (MS), but 3D-T1 imaging required for brain volumetrics is …
Predictive MRI biomarkers in MS—A critical review
Background and Objectives: In this critical review, we explore the potential use of MRI
measurements as prognostic biomarkers in multiple sclerosis (MS) patients, for both …
measurements as prognostic biomarkers in multiple sclerosis (MS) patients, for both …
Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption
BA Singer, J Feng, H Chiong-Rivero - Journal of Neurology, 2024 - Springer
Multiple sclerosis (MS) is characterized by progressive neuroinflammation and
neurodegeneration from disease onset that, if left untreated, can result in the accumulation …
neurodegeneration from disease onset that, if left untreated, can result in the accumulation …
The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease-modifying therapies were initiated from 2013 to 2021
AIMS: Multiple sclerosis treatment strategies are changing in the Czech Republic. According
to data from 2013-2021, the proportion of patients starting high-efficacy disease-modifying …
to data from 2013-2021, the proportion of patients starting high-efficacy disease-modifying …
[HTML][HTML] Brain atrophy measurement over a MRI scanner change in multiple sclerosis
T Sinnecker, S Schädelin, P Benkert, E Ruberte… - NeuroImage: Clinical, 2022 - Elsevier
Background A change in MRI hardware impacts brain volume measurements. The aim of
this study was to use MRI data from multiple sclerosis (MS) patients and healthy control …
this study was to use MRI data from multiple sclerosis (MS) patients and healthy control …